Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) has received a consensus rating of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued a report on the stock in the last year is $22.63.
A number of research analysts recently weighed in on ATEC shares. Wells Fargo & Company started coverage on Alphatec in a report on Friday. They set an “overweight” rating and a $26.00 target price on the stock. Needham & Company LLC upped their price objective on Alphatec from $16.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, December 19th. Stifel Nicolaus decreased their price objective on Alphatec from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Roth Mkm assumed coverage on Alphatec in a report on Friday, October 20th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, Morgan Stanley decreased their price objective on Alphatec from $23.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, November 14th.
Institutional Investors Weigh In On Alphatec
Several institutional investors and hedge funds have recently made changes to their positions in ATEC. BluePath Capital Management LLC acquired a new stake in Alphatec in the third quarter valued at approximately $29,000. Macquarie Group Ltd. bought a new position in shares of Alphatec in the first quarter valued at approximately $40,000. Lazard Asset Management LLC bought a new position in shares of Alphatec in the second quarter valued at approximately $49,000. Comerica Bank bought a new position in shares of Alphatec in the third quarter valued at approximately $36,000. Finally, State of Wyoming lifted its holdings in shares of Alphatec by 59.1% in the second quarter. State of Wyoming now owns 3,763 shares of the medical technology company’s stock valued at $68,000 after purchasing an additional 1,398 shares in the last quarter. Institutional investors and hedge funds own 67.19% of the company’s stock.
Alphatec Stock Down 2.4 %
NASDAQ:ATEC opened at $16.38 on Thursday. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -10.85 and a beta of 1.67. Alphatec has a twelve month low of $8.66 and a twelve month high of $19.14. The stock’s 50 day moving average price is $14.99 and its two-hundred day moving average price is $13.70.
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization.
- Five stocks we like better than Alphatec
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 attractive stocks that insiders are buying
- ETF Screener: Uses and Step-by-Step Guide
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Insider Trades May Not Tell You What You Think
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.